Compare DV & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DV | ATAI |
|---|---|---|
| Founded | 2008 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.6B |
| IPO Year | 2021 | 2025 |
| Metric | DV | ATAI |
|---|---|---|
| Price | $10.81 | $5.08 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 15 | 8 |
| Target Price | ★ $16.37 | $15.88 |
| AVG Volume (30 Days) | 2.8M | ★ 5.6M |
| Earning Date | 05-06-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.04 | N/A |
| Revenue | ★ $748,291,000.00 | $4,089,000.00 |
| Revenue This Year | $12.68 | N/A |
| Revenue Next Year | $9.75 | N/A |
| P/E Ratio | $248.75 | ★ N/A |
| Revenue Growth | 13.92 | ★ 1227.60 |
| 52 Week Low | $7.61 | $2.16 |
| 52 Week High | $16.82 | $6.73 |
| Indicator | DV | ATAI |
|---|---|---|
| Relative Strength Index (RSI) | 57.86 | 70.85 |
| Support Level | $10.71 | $4.96 |
| Resistance Level | $11.06 | $5.51 |
| Average True Range (ATR) | 0.40 | 0.33 |
| MACD | 0.02 | 0.09 |
| Stochastic Oscillator | 90.32 | 88.36 |
DoubleVerify Holdings Inc is a media effectiveness platform that leverages artificial intelligence (AI) to drive superior outcomes for international brands by creating transparent ad transactions. Its solutions provide unbiased data analytics to improve the effectiveness, quality and return on advertising investments. DV Authentic Ad is its proprietary metric measuring whether an ad was delivered in a brand suitable environment, fully viewable, by a real person and in geography, while DV Pinnacle delivers these metrics in real time. The Company's solutions are integrated across programmatic platforms, social media channels and digital publishers, and are accredited by the Media Rating Council for digital ad measurement. It operates in the United States and international markets.
AtaiBeckley Inc is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments. AtaiBeckley's pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD, and EMP-01 ((R)-MDMA HCI) for social anxiety disorder, which are in Phase 2 clinical development.